Glucose-6-Phosphate Dehydrogenase (G-6-PD) deficiency is the most important disorder of the pentose phosphate pathway in erythrocyte metabolism resulting in decreased activity of the enzyme. G-6-PD deficiency has been reported to be common in populations living in malaria endemic areas. Certain drugs that are used in the treatment of malaria and other conditions are known to induce hemolysis in G-6-PD deficient individuals. This study was carried out to determine the prevalence of G-6-PD deficiency in individuals with malaria infection. One hundred subjects were recruited in the study with 50 individuals positive for malaria infection as test subjects and 50 negatives for malaria infection serving as controls. A G-6-PD deficiency prevalence of 14% was found in the study, 86% of the G-6-PD deficient individuals were from the control group while 14% were from the malaria positive group. A significant difference (p≤0.01) in G-6-PD deficiency was found between the malaria group and the control group. Among the G-6-PD deficient individuals 93% were males. There was a significant (p≤0.05) difference in Packed Cell Volume and hemoglobin levels between the G-6-PD deficient group and the G-6-PD normal group. The lower prevalence of G-6-PD deficiency among the malaria group compared to the control group validates studies linking G-6-PD deficiency with malaria. Also, the higher prevalence seen in control group and males, suggests that gender plays an important role in this enzyme deficiency hence the need for G-6-PD screening in our community given the overuse of agents that may predispose a G-6-PD deficient individual to oxidative stress which could cause some hematological complications such as hemolytic anemia.